Strongbridge Biopharma plc.
SBBP
SBBP was delisted on the 5th of October, 2021.
51 hedge funds and large institutions have $135M invested in Strongbridge Biopharma plc. in 2019 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 7 closing their positions.
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
21% more funds holding
Funds holding: 42 → 51 (+9)
14% more capital invested
Capital invested by funds: $119M → $135M (+$16.4M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $26K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$4.5M |
| 2 |
D.E. Shaw & Co
New York
|
+$1.98M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$921K |
| 4 |
TI
Telemetry Investments
New York
|
+$613K |
| 5 |
Goldman Sachs
New York
|
+$379K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCS
Harvest Capital Strategies
San Francisco,
California
|
-$2.44M |
| 2 |
AC
Armistice Capital
New York
|
-$1.9M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.17M |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$999K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$560K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
BNP Paribas Financial Markets
Paris,
France
| $154 | – | – | – |
|
|
HCS
52
Harvest Capital Strategies
San Francisco,
California
| – | -$2.44M | -543,652 | Closed |
|
|
PP
53
PDT Partners
New York
| – | -$183K | -40,800 | Closed |
|
54
Two Sigma Investments
New York
| – | -$182K | -40,590 | Closed |
|
|
SIM
55
Spark Investment Management
New York
| – | -$146K | -32,800 | Closed |
|
|
OAM
56
Oxford Asset Management
Oxford,
United Kingdom
| – | -$110K | -24,593 | Closed |
|
|
BCM
57
Bayesian Capital Management
Brooklyn,
New York
| – | -$102K | -22,700 | Closed |
|
|
RG
58
Redmile Group
San Francisco,
California
| – | -$56K | -12,500 | Closed |
|
SBBP Hedge Fund Activity: Q1 2019 in Review
51 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q1 2019, worth a combined $135M — up 14% from $119M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SBBP positions and 7 closed out — a net gain of 9 holders — while 16 added to existing stakes and 12 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $4.5M. The largest seller was Harvest Capital Strategies, exiting entirely with an estimated $2.44M sold.
- 51 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q1 2019, up from 42 in Q4 2018.
- Funds reported $135M of Strongbridge Biopharma plc. stock for Q1 2019, up 14% quarter-over-quarter.
- 16 funds opened new Strongbridge Biopharma plc. positions in Q1 2019 and 7 closed out, a net change of +9 holders.
- The largest Strongbridge Biopharma plc. buyer in Q1 2019 was Vivo Capital, an estimated $4.5M added.
- The largest Strongbridge Biopharma plc. seller in Q1 2019 was Harvest Capital Strategies, an estimated $2.44M sold.
Based on aggregated 13F filings for Q1 2019.